The genetic basis of cancer of the kidney.

Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature (2013) 13.60

The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol (2010) 5.04

Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res (2008) 4.02

Single nucleotide polymorphisms of microRNA machinery genes modify the risk of renal cell carcinoma. Clin Cancer Res (2008) 2.11

Structured assessment and followup for patients with hereditary kidney tumour syndromes. Can Urol Assoc J (2016) 2.01

Molecular diagnosis and therapy of kidney cancer. Annu Rev Med (2010) 1.82

An investigation of risk factors for renal cell carcinoma by histologic subtype in two case-control studies. Int J Cancer (2013) 1.71

The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn) (2015) 1.59

Targeted therapy in renal cell carcinoma. World J Urol (2008) 1.56

Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics. Genome Res (2012) 1.49

Ror2, a developmentally regulated kinase, promotes tumor growth potential in renal cell carcinoma. Oncogene (2009) 1.48

A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Invest New Drugs (2006) 1.46

Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma. Oncogene (2005) 1.45

Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer (2008) 1.43

Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors. PLoS Genet (2011) 1.43

Feasibility and outcomes of repeat partial nephrectomy. J Urol (2008) 1.41

Hereditary kidney cancer: unique opportunity for disease-based therapy. Cancer (2009) 1.32

Germline E-cadherin mutations in familial lobular breast cancer. J Med Genet (2007) 1.28

The von Hippel-Lindau tumor suppressor gene product represses oncogenic beta-catenin signaling in renal carcinoma cells. Proc Natl Acad Sci U S A (2006) 1.27

HIF and fumarate hydratase in renal cancer. Br J Cancer (2007) 1.27

Renal cancer in von Hippel-Lindau disease and related syndromes. Nat Rev Nephrol (2013) 1.23

Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity. Mol Cell Biol (2005) 1.22

Partial nephrectomy after previous radio frequency ablation: the National Cancer Institute experience. J Urol (2009) 1.21

Accurate molecular classification of renal tumors using microRNA expression. J Mol Diagn (2010) 1.19

Oncological outcomes of partial nephrectomy for multifocal renal cell carcinoma greater than 4 cm. J Urol (2010) 1.18

Tuberous sclerosis and the kidney: from mesenchyme to epithelium, and beyond. Pediatr Nephrol (2005) 1.15

Papillary renal cell carcinoma within a renal oncocytoma: case report of an incidental finding of a tumour within a tumour. J Clin Pathol (2007) 1.14

Initial experience with robot assisted partial nephrectomy for multiple renal masses. J Urol (2009) 1.11

The metabolic basis of kidney cancer. Semin Cancer Biol (2012) 1.09

Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment. Onco Targets Ther (2012) 1.08

Update on targeted therapies for clear cell renal cell carcinoma. Curr Opin Oncol (2011) 1.08

Identification of genes and pathways involved in kidney renal clear cell carcinoma. BMC Bioinformatics (2014) 1.05

Expression of ROR1 in patients with renal cancer--a potential diagnostic marker. Iran Biomed J (2010) 1.04

The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy. Kidney Int (2009) 1.03

Genomic copy number alterations in clear cell renal carcinoma: associations with case characteristics and mechanisms of VHL gene inactivation. Oncogenesis (2012) 1.03

The clinical implications of the genetics of renal cell carcinoma. Urol Oncol (2009) 1.03

Targeted therapies for non-clear renal cell carcinoma. Target Oncol (2010) 1.02

Neutrophil chemokines secreted by tumor cells mount a lung antimetastatic response during renal cell carcinoma progression. Oncogene (2012) 1.00

Hereditary leiomyomatosis and renal cell carcinoma. Int J Nephrol Renovasc Dis (2014) 0.99

Racial difference in histologic subtype of renal cell carcinoma. Cancer Med (2013) 0.96

Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy. Expert Opin Biol Ther (2008) 0.96

HGIMDA: Heterogeneous graph inference for miRNA-disease association prediction. Oncotarget (2016) 0.95

Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications. Mol Cancer Ther (2014) 0.95

Cancers of the urinary tract among American Indians and Alaska Natives in the United States, 1999-2004. Cancer (2008) 0.94

Feasibility and outcomes of partial nephrectomy for resection of at least 20 tumors in a single renal unit. J Urol (2010) 0.93

Tumor cell invasion of von Hippel Lindau renal cell carcinoma cells is mediated by membrane type-1 matrix metalloproteinase. Mol Cancer (2006) 0.91

Partial nephrectomy for selected renal cortical tumours of ≥ 7 cm. BJU Int (2010) 0.91

Kidney cancer. Urol Oncol (2012) 0.91

Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions. Hematol Oncol Clin North Am (2011) 0.90

Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent. Anticancer Res (2009) 0.87

Multiple cutaneous and uterine leiomyomatosis syndrome: a review. J Clin Aesthet Dermatol (2013) 0.87

Impact of genetics on the diagnosis and treatment of renal cancer. Curr Urol Rep (2011) 0.87

Renal Tumor Quantification and Classification in Contrast-Enhanced Abdominal CT. Pattern Recognit (2009) 0.87

NFAT5-mediated expression of S100A4 contributes to proliferation and migration of renal carcinoma cells. Front Physiol (2014) 0.85

Advances in renal cell carcinoma treatment. Ther Adv Urol (2010) 0.84

Targeted therapies in the management of renal cell carcinoma: role of bevacizumab. Biologics (2008) 0.84

Metastatic non-clear cell renal cell carcinoma: an evidence based review of current treatment strategies. Front Oncol (2015) 0.83

Molecular sub-classification of renal epithelial tumors using meta-analysis of gene expression microarrays. PLoS One (2011) 0.83

Expression and prognostic significance of bcl-2 and bax in the progression and clinical outcome of transitional bladder cell carcinoma. Cell J (2013) 0.83

Genetic basis of bilateral renal cancer: implications for evaluation and management. J Clin Oncol (2009) 0.83

Renal oncocytoma: a comparative clinicopathologic study and fluorescent in-situ hybridization analysis of 73 cases with long-term follow-up. Diagn Pathol (2010) 0.82

Incidence and long-term prognosis of papillary renal cell carcinoma. J Cancer Res Clin Oncol (2008) 0.81

The genetic basis of kidney cancer: implications for management and use of targeted therapeutic approaches. Eur Urol (2012) 0.81

Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus. Oncotarget (2014) 0.81

Increased serum hepcidin-25 level and increased tumor expression of hepcidin mRNA are associated with metastasis of renal cell carcinoma. BMC Cancer (2009) 0.81

Autocrine MCP-1/CCR2 signaling stimulates proliferation and migration of renal carcinoma cells. Oncol Lett (2016) 0.80

Active surveillance for metastatic or recurrent renal cell carcinoma. J Cancer Res Clin Oncol (2014) 0.80

Application of ex vivo (1)H NMR metabonomics to the characterization and possible detection of renal cell carcinoma metastases. J Cancer Res Clin Oncol (2012) 0.80

[Von-Hippel-Lindau gene mutation types. Association of gene expression signatures in clear cell renal cell carcinoma]. Pathologe (2008) 0.80

Synthetic Bax-Anti Bcl2 combination module actuated by super artificial hTERT promoter selectively inhibits malignant phenotypes of bladder cancer. J Exp Clin Cancer Res (2016) 0.79

Renal medullary-like carcinoma in an adult without sickle cell hemoglobinopathy. Nat Rev Urol (2010) 0.79

Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma. Br J Cancer (2011) 0.79

Bioinformatics analysis and expression study of fumarate hydratase in lung cancer. Thorac Cancer (2014) 0.79

Differential genetic expression in large versus small clear cell renal cell carcinoma: results from microarray analysis. J Cancer (2011) 0.79

Current understanding of the molecular mechanisms of kidney cancer: a primer for urologists. Can Urol Assoc J (2007) 0.78

Repeat Robotic Partial Nephrectomy: Characteristics, Complications, and Renal Functional Outcomes. J Endourol (2016) 0.78

Basic Parameters of Blood Count as Prognostic Factors for Renal Cell Carcinoma. Biomed Res Int (2016) 0.78

High Level of Anaphylatoxin C5a Predicts Poor Clinical Outcome in Patients with Clear Cell Renal Cell Carcinoma. Sci Rep (2016) 0.77

Two single nucleotide polymorphisms in the von Hippel-Lindau tumor suppressor gene in Taiwanese with renal cell carcinoma. BMC Res Notes (2014) 0.77

Comparative studies of the proteome, glycoproteome, and N-glycome of clear cell renal cell carcinoma plasma before and after curative nephrectomy. J Proteome Res (2014) 0.77

Pazopanib for the treatment of patients with advanced renal cell carcinoma. Clin Med Insights Oncol (2010) 0.76

Microarray gene expression profiling using core biopsies of renal neoplasia. Am J Transl Res (2009) 0.76

The impact of germline BHD mutation on histological concordance and clinical treatment of patients with bilateral renal masses and known unilateral oncocytoma. J Urol (2011) 0.76

Genomic investigation of etiologic heterogeneity: methodologic challenges. BMC Med Res Methodol (2014) 0.76

Familial renal cancer: molecular genetics and surgical management. Int J Surg Oncol (2011) 0.76

Hereditary renal cell carcinoma: genetics, clinical features, and surgical considerations. World J Urol (2014) 0.76

Fibroblast Growth Factor Receptor-Dependent and -Independent Paracrine Signaling by Sunitinib-Resistant Renal Cell Carcinoma. Mol Cell Biol (2016) 0.76

Renal cell carcinoma risk is associated with the interactions of APOE, VHL and MTHFR gene polymorphisms. Int J Clin Exp Pathol (2015) 0.76

A Case of Reed's Syndrome: An Underdiagnosed Tumor Disorder. Case Rep Dermatol (2014) 0.75

Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial. Ann Oncol (2016) 0.75

Metabolism-related enzyme alterations identified by proteomic analysis in human renal cell carcinoma. Onco Targets Ther (2016) 0.75

Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma. Biologics (2010) 0.75

Review of US Comparative Economic Evidence for Treatment of Metastatic Renal Cell Carcinoma after Failure of First-Line VEGF Inhibitor Therapy. Am Health Drug Benefits (2013) 0.75

Molecular profiling of renal cell carcinoma: building a bridge toward clinical impact. Curr Opin Urol (2016) 0.75

Novel therapies in genitourinary cancer: an update. J Hematol Oncol (2008) 0.75

Familial syndromes coupling with small renal masses. Adv Urol (2008) 0.75

Genetic predisposition to kidney cancer. Semin Oncol (2016) 0.75

The changing face of renal-cell carcinoma. J Endourol (2010) 0.75

Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy. Drug Des Devel Ther (2017) 0.75

Identifying prognostic biomarkers based on aberrant DNA methylation in kidney renal clear cell carcinoma. Oncotarget (2016) 0.75

HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell (2005) 5.47

Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. Cancer Cell (2002) 5.10

Biochemical diagnosis of pheochromocytoma: which test is best? JAMA (2002) 4.84

Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res (2008) 4.02

Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci U S A (2006) 3.51

Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. Am J Hum Genet (2005) 3.26

Renal tumors in the Birt-Hogg-Dubé syndrome. Am J Surg Pathol (2002) 3.06

Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet (2003) 2.88

High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors. J Natl Cancer Inst (2005) 2.70

Evaluation and management of renal tumors in the Birt-Hogg-Dubé syndrome. J Urol (2005) 2.33

The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. J Urol (2004) 2.32

Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. J Natl Cancer Inst (2008) 2.25

Lung cysts, spontaneous pneumothorax, and genetic associations in 89 families with Birt-Hogg-Dubé syndrome. Am J Respir Crit Care Med (2007) 2.19

Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest (2002) 1.93

Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J Urol (2007) 1.86

Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location. Hum Mutat (2004) 1.78

Percutaneous radio frequency ablation of small renal tumors: initial results. J Urol (2002) 1.74

Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab (2003) 1.70

Expression of Birt-Hogg-Dubé gene mRNA in normal and neoplastic human tissues. Mod Pathol (2004) 1.67

A mutation in the canine BHD gene is associated with hereditary multifocal renal cystadenocarcinoma and nodular dermatofibrosis in the German Shepherd dog. Hum Mol Genet (2003) 1.66

Effects of different fixatives on beta-galactosidase activity. J Histochem Cytochem (2002) 1.63

Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor. Proc Natl Acad Sci U S A (2003) 1.53

Focus on kidney cancer. Cancer Cell (2004) 1.53

Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines. Clin Chem (2005) 1.52

Hepatic vascular tumors, angiectasis in multiple organs, and impaired spermatogenesis in mice with conditional inactivation of the VHL gene. Cancer Res (2003) 1.46

Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin Cancer Res (2004) 1.45

Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. J Urol (2012) 1.45

Thermal protection during percutaneous thermal ablation of renal cell carcinoma. J Vasc Interv Radiol (2004) 1.42

A germ-line insertion in the Birt-Hogg-Dubé (BHD) gene gives rise to the Nihon rat model of inherited renal cancer. Proc Natl Acad Sci U S A (2004) 1.40

Percutaneous tumor ablation with radiofrequency. Cancer (2002) 1.31

Hereditary renal cancers. Radiology (2003) 1.31

Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the met proto-oncogene. J Urol (2004) 1.20

Partial adrenalectomy: the National Cancer Institute experience. Urology (2005) 1.12

Vascular defects and liver damage by the acute inactivation of the VHL gene during mouse embryogenesis. Lab Invest (2006) 1.00

The genetic basis of cancer of kidney cancer: implications for gene-specific clinical management. BJU Int (2005) 0.98

Neuroendocrine tumors of the pancreas in von Hippel-Lindau disease: spectrum of appearances at CT and MR imaging with histopathologic comparison. Radiology (2002) 0.98

Management of von Hippel-Lindau-associated kidney cancer. Nat Clin Pract Urol (2005) 0.95

Intraoperative ultrasound aids in dissection during laparoscopic partial adrenalectomy. J Urol (2002) 0.93

Laparoscopic management of extra-adrenal pheochromocytoma. J Urol (2004) 0.93

Somatic alterations contributing to metastasis of a castration-resistant prostate cancer. Hum Mutat (2013) 0.92

Assessment of risk for intra-abdominal adhesions at laparoscopy for urological tumors. J Urol (2002) 0.91

Parenchymal sparing surgery for central renal tumors in patients with hereditary renal cancers. J Urol (2004) 0.90

Utility of plasma free metanephrines for detecting childhood pheochromocytoma. J Clin Endocrinol Metab (2002) 0.90

Pheochromocytoma in von hippel-lindau disease: distinct histopathologic phenotype compared to pheochromocytoma in multiple endocrine neoplasia type 2. Endocr Pathol (2002) 0.87

Diagnostic localization of malignant bladder pheochromocytoma using 6-18F fluorodopamine positron emission tomography. J Urol (2003) 0.85

Differential expression of erythropoietin and its receptor in von hippel-lindau-associated and multiple endocrine neoplasia type 2-associated pheochromocytomas. J Clin Endocrinol Metab (2005) 0.84

Disruption of a novel MFS transporter gene, DIRC2, by a familial renal cell carcinoma-associated t(2;3)(q35;q21). Hum Mol Genet (2002) 0.84

Surgical management of lumbosacral nerve root hemangioblastomas in von Hippel-Lindau syndrome. J Neurosurg (2003) 0.83

Surgical management of multi-organ visceral tumors in patients with von Hippel-Lindau disease: a single stage approach. J Urol (2003) 0.83

Radiofrequency ablation of cancer. Cardiovasc Intervent Radiol (2004) 0.83

A phase I study of intravesical suramin for the treatment of superficial transitional cell carcinoma of the bladder. J Urol (2003) 0.82

Risk factors for skin breakdown after renal and adrenal surgery. Urology (2004) 0.78

A novel laparoscopic specimen entrapment device to facilitate morcellation of large renal tumors. Urology (2002) 0.77

Laparoscopic radical nephrectomy for advanced kidney cancer. Curr Urol Rep (2002) 0.76

Hereditary kidney cancer. Urol Clin North Am (2003) 0.76

Facial papules, spontaneous pneumothorax, and renal tumors. J Am Acad Dermatol (2003) 0.76

Transperitoneal laparoscopic radical nephrectomy for bulky renal tumors. Can J Urol (2002) 0.75

Metastatic renal cell carcinoma to contralateral ureter presenting as acute obstructive renal failure after radical nephrectomy. Urology (2005) 0.75

Surgical images: Soft tissue laparoscopic resection of a renal hilar pheochromocytoma. Can J Surg (2004) 0.75

Update on minimally invasive approaches to kidney tumors. Curr Urol Rep (2004) 0.75

Specimen morcellation after laparoscopic radical nephrectomy: confirmation of histologic diagnosis using needle biopsy. J Endourol (2002) 0.75

Bilateral testicular adrenal rests after bilateral adrenalectomies in a cushingoid patient with von Hippel-Lindau disease. Urology (2004) 0.75

Intentional resection of the diaphragm during cytoreductive laparoscopic radical nephrectomy. J Urol (2002) 0.75